TREATMENT OF LEPTOMENINGEAL CARCINOMATOSIS WITH CONTINUOUS INTRAVENTRICULAR INFUSION OF RECOMBINANT INTERLEUKIN-2

被引：17
作者：
HEIMANS, JJ
WAGSTAFF, J
SCHREUDER, WO
WOLBERS, JG
BAARS, JW
POLMAN, CH
SCHARENBERG, JG
SCHEPER, RJ
PALMER, PA
FRANKS, CR
机构：
[1] FREE UNIV AMSTERDAM HOSP, DEPT NEUROSURG, 1007 MB AMSTERDAM, NETHERLANDS
[2] FREE UNIV AMSTERDAM HOSP, DEPT MED ONCOL, 1007 MB AMSTERDAM, NETHERLANDS
[3] FREE UNIV AMSTERDAM HOSP, DEPT IMMUNOL, 1007 MB AMSTERDAM, NETHERLANDS
[4] EUROCETUS, AMSTERDAM, NETHERLANDS
来源：
SURGICAL NEUROLOGY | 1991年 / 35卷 / 03期
关键词：
LEPTOMENINGEAL CARCINOMATOSIS; MELANOMA; INTERLEUKIN-2; INTRAVENTRICULAR TREATMENT;
D O I：
10.1016/0090-3019(91)90079-O
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 42-year-old man developed leptomeningeal carcinomatosis 6 years after treatment of a malignant melanoma. He was treated with two courses of recombinant interleukin-2, administered as a continuous intraventricular infusion (6 x 10E5 U/24 h) during 5 days. During the first day of the first course he also received 5 x 10E9 lymphokine-activated killer cells intraventricularly. This gave rise to a severe elevation of intracranial pressure, with headaches and meningismus. During the second course no LAK cells were administered. This course was tolerated much better. The neurological status did not change during the treatment. Recombinant interleukin-2 levels were maintained at about 300 U/mL during both courses.
引用
收藏
页码：244 / 247
页数：4
相关论文
共 16 条
[1]   INTRAVENTRICULAR METHOTREXATE THERAPY OF LEPTOMENINGEAL METASTASIS FROM BREAST-CARCINOMA [J].
DEVISSER, BWO ;
SOMERS, R ;
NOOYEN, WH ;
VANHEERDE, P ;
HART, AM ;
MCVIE, JG .
NEUROLOGY, 1983, 33 (12) :1565-1572
[2]  
GUSTAVSON LE, 1989, J BIOL RESP MODIF, V8, P440
[3]  
JACOBS SK, 1987, NEW ENGL J MED, V317, P962
[4]  
LOTZE MT, 1980, J IMMUNOL, V125, P1487
[5]   INFILTRATION OF LEPTOMENINGES BY SYSTEMIC CANCER - CLINICAL AND PATHOLOGIC-STUDY [J].
OLSON, ME ;
CHERNIK, NL ;
POSNER, JB .
ARCHIVES OF NEUROLOGY, 1974, 30 (02) :122-137
[6]   EXPERIENCE WITH THE USE OF HIGH-DOSE INTERLEUKIN-2 IN THE TREATMENT OF 652 CANCER-PATIENTS [J].
ROSENBERG, SA ;
LOTZE, MT ;
YANG, JC ;
AEBERSOLD, PM ;
LINEHAN, WM ;
SEIPP, CA ;
WHITE, DE .
ANNALS OF SURGERY, 1989, 210 (04) :474-485
[7]   PENETRATION OF RECOMBINANT INTERLEUKIN-2 ACROSS THE BLOOD-CEREBROSPINAL FLUID BARRIER [J].
SARIS, SC ;
ROSENBERG, SA ;
FRIEDMAN, RB ;
RUBIN, JT ;
BARBA, D ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1988, 69 (01) :29-34
[8]  
SHAPIRO WR, 1977, CANCER TREAT REP, V61, P733
[9]   ADOPTIVE IMMUNOTHERAPY OF HUMAN MENINGEAL GLIOMATOSIS AND CARCINOMATOSIS WITH LAK CELLS AND RECOMBINANT INTERLEUKIN-2 [J].
SHIMIZU, K ;
OKAMOTO, Y ;
MIYAO, Y ;
YAMADA, M ;
USHIO, Y ;
HAYAKAWA, T ;
IKEDA, H ;
MOGAMI, H .
JOURNAL OF NEUROSURGERY, 1987, 66 (04) :519-521
[10]   MENINGEAL CARCINOMATOSIS [J].
THEODORE, WH ;
GENDELMAN, S .
ARCHIVES OF NEUROLOGY, 1981, 38 (11) :696-699
12